Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 In vitro susceptibility of isolates of Aspergillus fumigatus and Sporothrix schenckii to amphotericin B.

Literature DB >> 4670509

In vitro susceptibility of isolates of Aspergillus fumigatus and Sporothrix schenckii to amphotericin B.

Abstract

The in vitro susceptibility of 21 isolates of Aspergillus fumigatus and 12 isolates of Sporothrix schenckii to amphotericin B was determined. The minimal inhibitory concentration (MIC) for the A. fumigatus isolates ranged from 0.14 to 0.6 mug of drug per ml. The mean MIC for the 21 isolates was 0.33 mug per ml. The MIC for the 12 S. schenckii isolates ranged from 0.68 to 2.12 mug of drug per ml, with a mean MIC of 1.38 mug per ml.

Entities: Chemical Species

Mesh：

Substances：
Amphotericin B

Year: 1972 PMID： 4670509 PMCID： PMC444327 DOI： 10.1128/AAC.2.5.402

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

13 in total

1. TREATMENT OF PULMONARY ASPERGILLOMA WITH AMPHOTERICIN B.

Authors: H IKEMOTO
Journal: Arch Intern Med Date: 1965-05

2. Some aspects of the absorption, distribution, and excretion of amphotericin B in man.

Authors: D B LOURIA
Journal: Antibiotic Med Clin Ther (New York) Date: 1958-05

3. A pharmacologic guide to the clinical use of amphotericin B.

Authors: D D Bindschadler; J E Bennett
Journal: J Infect Dis Date: 1969-10 Impact factor: 5.226

4. Susceptibility of Aspergillus to steroids, amphotericin B, and nystatin.

Authors: J A Mohr; B A McKown; H G Muchmore
Journal: Am Rev Respir Dis Date: 1971-02

5. In vitro susceptibility of Cryptococcus neoformans to amphotericin B, hamycin, and 5-fluorocytosine.

Authors: S Shadomy; H J Shadomy; J A McCay; J P Utz
Journal: Antimicrob Agents Chemother (Bethesda) Date: 1968

6. Antifungal drugs for oculomycosis. II. Sensitivity of certain ocular fungi to antifungal drugs.

Authors: Y M Clayton
Journal: Trans Ophthalmol Soc U K Date: 1970

7. In vitro antifungal activity of clotrimazole (Bay b 5097).

Authors: S Shadomy
Journal: Infect Immun Date: 1971-08 Impact factor: 3.441

8. In vitro sensitivity of Torulopsis glabrata to amphotericin B, 5-fluorocytosine, and clotrimazole (Bay 5097).

Authors: M I Marks; P Steer; T C Eickhoff
Journal: Appl Microbiol Date: 1971-07

9. Amphotericin B serum concentrations during therapy.

Authors: B T Fields; J H Bates; R S Abernathy
Journal: Appl Microbiol Date: 1970-06

11 in total

1. Stability of amphotericin B in fungal culture media.

Authors: S C Cheung; G Medoff; D Schlessinger; G S Kobayashi
Journal: Antimicrob Agents Chemother Date: 1975-10 Impact factor: 5.191

2. Characterization of the binding of amphotericin B to Saccharomyces cerevisiae and relationship to the antifungal effects.

Authors: J Kotler-Brajtburg; G Medoff; D Schlessinger; G S Kobayashi
Journal: Antimicrob Agents Chemother Date: 1974-12 Impact factor: 5.191

In vitro susceptibility of isolates of Aspergillus fumigatus and Sporothrix schenckii to amphotericin B.

1. TREATMENT OF PULMONARY ASPERGILLOMA WITH AMPHOTERICIN B.

2. Some aspects of the absorption, distribution, and excretion of amphotericin B in man.

3. A pharmacologic guide to the clinical use of amphotericin B.

4. Susceptibility of Aspergillus to steroids, amphotericin B, and nystatin.

5. In vitro susceptibility of Cryptococcus neoformans to amphotericin B, hamycin, and 5-fluorocytosine.

6. Antifungal drugs for oculomycosis. II. Sensitivity of certain ocular fungi to antifungal drugs.

7. In vitro antifungal activity of clotrimazole (Bay b 5097).

8. In vitro sensitivity of Torulopsis glabrata to amphotericin B, 5-fluorocytosine, and clotrimazole (Bay 5097).

9. Amphotericin B serum concentrations during therapy.

1. Stability of amphotericin B in fungal culture media.

2. Characterization of the binding of amphotericin B to Saccharomyces cerevisiae and relationship to the antifungal effects.

3. Standardization of a hyphal inoculum of aspergilli for amphotericin B susceptibility testing.

4. Rapid and highly reproducible method for antifungal susceptibility testing of Aspergillus species.

5. Antimicrobial susceptibility testing of six clinical isolates of Aspergillus.

6. Molecular identification of Sporothrix clinical isolates in China.

7. Polyene-resistant mutants of Aspergillus fennelliae: sterol content and genetics.

8. Determination of the minimal inhibitory concentration of amphotericin B and miconazole for 21 strains of Aspergillus.

9. In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.

10. Minimal inhibitory concentrations of lucknomycin, a new polyenic derivative, for Candida and Aspergillus spp.